Reduced striatal dopaminergic innervation shown by IPT and SPECT in patients under neuroleptic treatment: Need for levodopa therapy

Psychiatry Research - Neuroimaging

Volumn 83, Issue 1, 1998, Pages 23-28

  Schwarz, Johannes ^a,e   Scherer, Josef ^b   Trenkwalder, Claudia ^c   Mozley, P David ^d   Tatsch, Klaus ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b KLINIKUM MÜNCHEN OST   (Germany)

^c MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF ULM   (Germany)

Author keywords

Dopamine transporter imaging; Parkinson's disease; Schizophrenia; SPECT; Substantia nigra

Indexed keywords

CLOZAPINE; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORTER; FLUPENTIXOL; HALOPERIDOL; IODINE 123; LEVODOPA; LISURIDE; N (3 IODOPROPEN 2 YL) 2BETA CARBOMETHOXY 3BETA (4 CHLOROPHENYL)TROPANE; NEUROLEPTIC AGENT; PROMETHAZINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CASE REPORT; CAUDATE NUCLEUS; CORPUS STRIATUM; DOPAMINE UPTAKE; DOSE RESPONSE; FEMALE; HUMAN; MALE; NERVE ENDING; PARANOID PSYCHOSIS; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; CAUDATE NUCLEUS; DOPAMINE; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOSTRIATUM; PARKINSON DISEASE; PUTAMEN; SCHIZOPHRENIA, PARANOID; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 0032528444     PISSN: 09254927     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0925-4927(98)00026-2     Document Type: Article

References (11)

1. American Psychiatric Association, 1987. DSM-III-R: Diagnostic and Statistical Manual of Mental Disorders, 3rd ed., revised. American Psychiatric Press, Washington, DC.
2. Chang L.T. A method for attenuation correction in radionuclide computed tomography. Institute of Electrical and Electronics Engineers Transactions on Nuclear Science. 25:1978;638-643.
3. Davis K.L., Kahn R.S., Ko G., Davidson M. Dopamine in schizophrenia: a review and reconceptualization. American Journal of Psychiatry. 148:1991;1474-1486.
4. Friedman J.H., Max J., Swift R. Idiopathic Parkinson's disease in a chronic schizophrenic patient: long term treatment with clozapine and L-DOPA. Clinical Neuropharmacology. 10:1987;470-475.
5. Goodman M.M., Kung M.P., Kabalka G.W., Kung H.F., Switzer R. Synthesis and characterization of radioiodinated N-(3-iodopropen-1-yl)2β-carboxymethoxy-3β-(4-chlorophenyl) tropanes: potential dopamine reuptake site imaging agents. Journal of Medical Chemistry. 34:1994;1535-1542.
6. Höflich G., Burghof K.W., Kasper S., Möller H.J. Elektrokrampftherapie bei Komorbidität einer therapieresistenten paranoid-halluzinatorischen Psychose mit Morbus Parkinson. Nervenarzt. 65:1994;202-205.
7. Innis R.B., Seibyl J.P., Scanley B.E., Laruelle M., Abi-Dargham A., Wallace E., Baldwin R.M., Zea-Ponce Y., Zoghbi S., Wang S. Single photon emission computed tomography demonstrates loss of striatal dopamine transporters in Parkinson's disease. Proceedings of the National Academy of Sciences USA. 90:1993;11965-11969.
8. Kung M.P., Essman W.D., Frederick D., Meegalla S., Goodman M., Mu M., Lucki I., Kung H.F. IPT: a novel iodinated ligand for the CNS dopamine transporter. Synapse. 20:1995;316-324.
9. Mozley P.D., Kim H.J., Gur R.C., Tatsch K., Muenz L.R., McElgin W.T., Kung M.-P., Mu M., Myers A.M., Kung H.F. I-123 IPT SPECT imaging of the CNS dopamine transporters: non-linear effects of normal aging on striatal uptake values. Journal of Nuclear Medicine. 37:1996;1965-1970.
10. Sedvall G., Farde L. Chemical brain anatomy in schizophrenia. Lancet. 346:1995;743-749.
11. Tatsch K., Schwarz J., Mozley P.D., Linke R., Pogarell O., Oertel W.H., Fieber R.S., Hahn K., Kung H.F. Relationship between clinical features of Parkinson's disease and presynaptic dopamine transporter binding assessed with (I-123)IPT and SPECT. European Journal of Nuclear Medicine. 24:1997;415-421.